Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790944 · ClinicalTrials.gov registry record
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
A clinical trial of Pancreatic Ductal Adenocarcinoma, sponsored by Ambry Genetics.
- Completed
- Registry status
- 300
- Enrollment target
- 3
- Study locations
NCT02790944 is a study of Pancreatic Ductal Adenocarcinoma that has completed, run by Ambry Genetics. The registered enrollment target is 300 participants, below the 597-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (50% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02790944, a study of Pancreatic Ductal Adenocarcinoma, has completed, sponsored by Ambry Genetics.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.
Conditions Studied
Interventions
- GENETIC Multi-gene Next Generation Sequencing Panel
Study Locations (3)
Arizona
- HonorHealth Research Institute - Scottsdale
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2016-05-04 |
| Est. Completion | 2020-08-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02790944
The ClinicalTrials.gov registry entry for NCT02790944 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 597-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (50% lower). The listed sponsor is Ambry Genetics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Multi-gene Next Generation Sequencing Panel is the first listed.
NCT02790944 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02790944 about?
NCT02790944 is a clinical study titled "Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer". The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.
What is the current status of trial NCT02790944?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2016-05-04. Estimated completion is 2020-08-15.
What conditions does trial NCT02790944 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT02790944?
The interventions under investigation include: Multi-gene Next Generation Sequencing Panel (GENETIC).
Who is sponsoring clinical trial NCT02790944?
This trial is sponsored by Ambry Genetics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02790944 being conducted?
This trial has 3 study locations across Arizona, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.